Dr. Cortes Discusses FLT3 Inhibitors in AML

J​orge E. Cortes, MD
Published: Thursday, Jun 22, 2017



Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 


Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x